OLAPARIB

Search structure
Trade Names:
Synonyms:
Status: Approved (2014)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: L01XK01
UNII: WOH1JD9AR8

Structure
InChI Key FDLYAMZZIXQODN-UHFFFAOYSA-N
Smile O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1
InChI
InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)

Physicochemical Descriptors

Property Name Value
Molecular Formula C24H23FN4O3
Molecular Weight 434.47
AlogP 2.35
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 4.0
Polar Surface Area 86.37
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 32.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR PARP 1, 2 and 3 inhibitor FDA
Primary Target
poly(ADP-ribose) polymerase 1
poly(ADP-ribose) polymerase 2
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Transferase
0-16000 1-2960 0 1 90-100

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Ovarian Neoplasms 4 D010051 ClinicalTrials
Ovarian Neoplasms 4 D010051 ClinicalTrials
Ovarian Neoplasms 4 D010051 ClinicalTrials
Neoplasms 4 D009369 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Fallopian Tube Neoplasms 3 D005185 ClinicalTrials
Peritoneal Neoplasms 3 D010534 ClinicalTrials
Endometrial Neoplasms 3 D016889 ClinicalTrials
Fallopian Tube Neoplasms 3 D005185 ClinicalTrials
Stomach Neoplasms 3 D013274 ClinicalTrials
Peritoneal Neoplasms 3 D010534 ClinicalTrials
Carcinoma 3 D002277 ClinicalTrials
Stomach Neoplasms 3 D013274 ClinicalTrials
Small Cell Lung Carcinoma 3 D055752 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Endometrial Neoplasms 3 D016889 ClinicalTrials
Endometrial Neoplasms 3 D016889 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 3 D064129 ClinicalTrials
Prostatic Neoplasms 3 D011471 ClinicalTrials
Prostatic Neoplasms 3 D011471 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 3 D002289 ClinicalTrials
Prostatic Neoplasms 3 D011471 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Lung Neoplasms 2 D008175 ClinicalTrials
Sarcoma, Ewing 2 D012512 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Neoplasms, Germ Cell and Embryonal 2 D009373 ClinicalTrials
Sarcoma 2 D012509 ClinicalTrials
Pancreatic Neoplasms 2 D010190 ClinicalTrials
Glioblastoma 2 D005909 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Pancreatic Neoplasms 2 D010190 ClinicalTrials
Colorectal Neoplasms 2 D015179 ClinicalTrials
Urinary Bladder Neoplasms 2 D001749 ClinicalTrials
Mesothelioma 2 D008654 ClinicalTrials
Carcinoma, Renal Cell 2 D002292 ClinicalTrials
Carcinoma, Pancreatic Ductal 2 D021441 ClinicalTrials
Hemangiosarcoma 2 D006394 ClinicalTrials
Cholangiocarcinoma 2 D018281 ClinicalTrials
Sarcoma 2 D012509 ClinicalTrials
Urinary Bladder Neoplasms 2 D001749 ClinicalTrials
Bile Duct Neoplasms 2 D001650 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Osteosarcoma 2 D012516 ClinicalTrials
Uterine Cervical Neoplasms 2 D002583 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Triple Negative Breast Neoplasms 2 D064726 ClinicalTrials
Uterine Cervical Neoplasms 2 D002583 ClinicalTrials
Head and Neck Neoplasms 1 D006258 ClinicalTrials
Hypertension, Pulmonary 1 D006976 ClinicalTrials
Neuroendocrine Tumors 1 D018358 ClinicalTrials
Lymphoma 1 D008223 ClinicalTrials
Central Nervous System Neoplasms 1 D016543 ClinicalTrials
Glioma 1 D005910 ClinicalTrials
Rhabdomyosarcoma 1 D012208 ClinicalTrials
Hereditary Breast and Ovarian Cancer Syndrome 1 D061325 ClinicalTrials
Uterine Neoplasms 1 D014594 ClinicalTrials
Neoplasm Metastasis 1 D009362 ClinicalTrials
Inflammatory Breast Neoplasms 1 D058922 ClinicalTrials

Related Entries

MCS

Scaffolds

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Gastrointestinal disorders
14.24
General disorders and administration site conditions
13.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
8.34
Blood and lymphatic system disorders
7.94
Injury, poisoning and procedural complications
7.48
Investigations
6.82
Nervous system disorders
6.59
Respiratory, thoracic and mediastinal disorders
5.68
Musculoskeletal and connective tissue disorders
4.51
Skin and subcutaneous tissue disorders
3.67
Cardiac disorders
3.29
Vascular disorders
3.25
Infections and infestations
3.06
Metabolism and nutrition disorders
2.8
Psychiatric disorders
2.67

Cross References

Resources Reference
CAS NUMBER 763113-22-0
ChEBI 83766
ChEMBL CHEMBL521686
DrugBank DB09074
DrugCentral 4907
FDA SRS WOH1JD9AR8
Guide to Pharmacology 7519
PDB 09L
PubChem 23725625
SureChEMBL SCHEMBL426568
ZINC ZINC000040430143
CONTENTS